338 related articles for article (PubMed ID: 25347226)
1. A decision support tool for appropriate glucose-lowering therapy in patients with type 2 diabetes.
Ampudia-Blasco FJ; Benhamou PY; Charpentier G; Consoli A; Diamant M; Gallwitz B; Khunti K; Mathieu C; Ridderstråle M; Seufert J; Tack C; Vilsbøll T; Phan TM; Stoevelaar H
Diabetes Technol Ther; 2015 Mar; 17(3):194-202. PubMed ID: 25347226
[TBL] [Abstract][Full Text] [Related]
2. Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries.
Heintjes EM; Overbeek JA; Hall GC; Prieto-Alhambra D; Lapi F; Hammar N; Bezemer ID
Clin Ther; 2017 Nov; 39(11):2296-2310.e14. PubMed ID: 29108837
[TBL] [Abstract][Full Text] [Related]
3. Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.
Cefalu WT; Buse JB; Del Prato S; Home PD; LeRoith D; Nauck MA; Raz I; Rosenstock J; Riddle MC
Diabetes Care; 2014 Sep; 37(9):2647-59. PubMed ID: 25147257
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
5. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
[TBL] [Abstract][Full Text] [Related]
6. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
7. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
Bailey T
Am J Med; 2013 Sep; 126(9 Suppl 1):S10-20. PubMed ID: 23953074
[TBL] [Abstract][Full Text] [Related]
8. What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?
Zenari L; Marangoni A
Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():17-25. PubMed ID: 24034516
[TBL] [Abstract][Full Text] [Related]
9. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
10. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
11. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.
Rathmann W; Bongaerts B; Kostev K
Diabetes Obes Metab; 2016 Aug; 18(8):840-3. PubMed ID: 27062643
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study.
Fu H; Curtis BH; Schuster DP; Festa A; Kendall DM
Diabetes Technol Ther; 2014 Dec; 16(12):833-9. PubMed ID: 25068375
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.
Liu SC; Chien KL; Wang CH; Chen WC; Leung CH
Endocr Pract; 2013; 19(6):980-8. PubMed ID: 23807528
[TBL] [Abstract][Full Text] [Related]
14. Glucose-lowering medicines for type 2 diabetes.
Davoren P
Aust Fam Physician; 2015 May; 44(5):176-9. PubMed ID: 26042396
[TBL] [Abstract][Full Text] [Related]
15. Diabetes update: new drugs to manage type 2 diabetes.
Erlich DR; Slawson DC; Shaughnessy A
FP Essent; 2013 May; 408():20-4. PubMed ID: 23690375
[TBL] [Abstract][Full Text] [Related]
16. [Management of type 2 diabetes: new or previous agents, how to choose?].
Halimi S
Presse Med; 2013 May; 42(5):861-70. PubMed ID: 23643613
[TBL] [Abstract][Full Text] [Related]
17. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.
Katsiki N; Kazakos K; Triposkiadis F
Expert Opin Pharmacother; 2022 Dec; 23(17):1957-1974. PubMed ID: 36322877
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
Home PD; Shamanna P; Stewart M; Yang F; Miller M; Perry C; Carr MC
Diabetes Obes Metab; 2015 Feb; 17(2):179-87. PubMed ID: 25406730
[TBL] [Abstract][Full Text] [Related]
19. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
Chakravarty A; Rastogi M; Dhankhar P; Bell KF
J Med Econ; 2018 May; 21(5):497-509. PubMed ID: 29376760
[TBL] [Abstract][Full Text] [Related]
20. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
Montvida O; Shaw JE; Blonde L; Paul SK
Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
